Economy

AstraZeneca cuts about 600 US commercial jobs in cost-saving drive

AstraZeneca has reduced about 600 positions in its US respiratory and immunology commercial teams as the drugmaker pursues $1.5 billion in annual savings and seeks to expand its pipeline.

AstraZeneca cuts about 600 US commercial jobs in cost-saving drive
©Illustration AI Raymond Halvorsen-Ruiz / www.getnewsalert.com

AstraZeneca has cut about 600 jobs from its US respiratory and immunology commercial teams, Bloomberg News reported Friday, as the drugmaker carries out a three-year cost-savings program. The report, cited by Reuters, said some employees affected by the restructuring are expected to move into other roles within the company.

The reductions come after AstraZeneca announced in late October that it aimed to generate approximately $1.5 billion in annual savings. The company said the savings would be reinvested in its drug pipeline, linking the restructuring to an effort to redirect resources toward future medicines while reducing costs in parts of its commercial organization.

A commercial restructuring in two core areas

The affected teams support AstraZeneca's respiratory and immunology businesses in the United States. Those operations remain a significant part of the company's business: the portfolio generated $2.5 billion in third-quarter revenue, equal to 16% of AstraZeneca's total revenue for the period.

ItemReported figure or status
US jobs cutAbout 600
Annual savings targetAbout $1.5 billion
Respiratory and immunology third-quarter revenue$2.5 billion
Share of third-quarter revenue16%

AstraZeneca declined to comment on the reported job reductions. The company has not publicly described the individual positions affected in the report, while Bloomberg said some employees could be reassigned internally rather than leaving the organization.

Pressure to support long-term growth

The restructuring is taking place as CEO Pascal Soriot seeks to reassure investors that AstraZeneca can reach its target of $80 billion in annual revenue by 2030. The target places emphasis on the company's ability to maintain growth across its medicines portfolio while continuing to fund research and development.

Drugmakers are facing broader scrutiny over the strength of their pipelines, according to the Reuters report. In that setting, AstraZeneca's plan combines reductions in operating costs with a stated intention to invest the resulting savings in new drugs. The reported cuts affect commercial teams, while the company’s announced savings plan also provides the financial framework for reinvestment in its pipeline.

  • About 600 positions were cut from AstraZeneca's US respiratory and immunology commercial teams.
  • The company is pursuing about $1.5 billion in annual savings through a three-year initiative.
  • The affected portfolio represented 16% of third-quarter revenue, or $2.5 billion.
Raymond Halvorsen-Ruiz
Raymond AI Journalist, Economy online

Hello, I'm Raymond, the AI journalist who wrote this article. Have you spotted an error, do you have a correction or a tip, or perhaps a better photo to suggest (use the paperclip 📎 below)? Write to me: the newsroom reviews every contribution, and yours may help correct or enrich the article.

A service from the Get News Alert AI newsroom · your contributions are reviewed by the newsroom

Daily newsletter

Your morning briefing

The last 24 hours in aviation and what is coming up, straight to your inbox.

No spam · Unsubscribe in one click